0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > BCMA

BCMA

Brief Information

Name:B-cell maturation protein
Target Synonym:B-Cell Maturation Protein,B-Cell Maturation Factor,B Cell Maturation Antigen,CD269 Antigen,Tumor Necrosis Factor Receptor Superfamily Member 17,TNFRSF17,TNFRSF13A,CD269,BCM,BCMA,TNF Receptor Superfamily Member 17,Tumor Necrosis Factor Receptor Superfamily, Member 17,B-Cell Maturation Antigen
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:89
Lastest Research Phase:Approved

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
BCMA VHH - 01 Lead Hematological Malignancy Multiple myeloma

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
CS1+BCMA CAR-T Cell therapy Oncology/Cancer MM IND Global(except Europe/Canada)

Product ListCompare or Buy

Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
CEA-B045 Human ClinMax™ Human Soluble BCMA ELISA Kit
MBS-C004 Human ActiveMax® Human BCMA μBeads, premium grade (for cells)
BCA-HA2H7 Human Alexa Fluor™ 555-Labeled Human BCMA / TNFRSF17 Protein, His TagStar Staining
BCA-HA2H7-structure
BCA-HA2H9 Human Alexa Fluor™ 647-Labeled Human BCMA / TNFRSF17 Protein, His TagStar Staining
BCA-HA2H9-structure
BCA-HA2H8 Human Alexa Fluor™ 488-Labeled Human BCMA / TNFRSF17 Protein, His TagStar Staining
BCA-HA2H8-structure
EP-127 Human BCMA [Biotinylated] : APRIL Inhibitor Screening ELISA Kit
EP-118 Human BCMA [Biotinylated] : BAFF Inhibitor Screening ELISA Kit
BCA-HA2H5 Human APC-Labeled Human BCMA / TNFRSF17 Protein, His Tag (Site-specific conjugation)
BCA-HA2H5-structure
BCA-HA2H4 Human APC-Labeled Human BCMA / TNFRSF17 Protein, His TagStar Staining
BCA-HA2H4-structure
BCA-HP2H7 Human PE-Labeled Human BCMA / TNFRSF17 Protein, His TagStar Staining
BCA-HP2H7-structure
BCA-C5257 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Llama IgG2b Fc Tag (MALS verified)
BCA-C5257-structure
BCA-C5257-sds
BCA-HF2H3 Human FITC-Labeled Human BCMA / TNFRSF17 Protein, His TagStar Staining
BCA-HF2H3-structure
BCA-HF2H3-sds
BCA-C52H3 Canine Canine BCMA / TNFRSF17 Protein, His Tag (MALS verified)
BCA-C52H3-structure
BCA-C52H3-sds
BCA-R52H3 Rat Rat BCMA / TNFRSF17 Protein, His Tag
BCA-R52H3-structure
BCA-R52H3-sds
BCA-R52H4 Rabbit Rabbit BCMA / TNFRSF17 Protein, His Tag
BCA-R52H4-structure
BCA-R52H4-sds
BCA-HP2H2 Human PE-Labeled Human BCMA / TNFRSF17 Protein, His Tag (Site-specific conjugation)
BCA-HP2H2-structure
BCA-C82E5 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, His,Avitag™
BCA-C82E5-structure
BCA-C82E5-sds
BCA-M43 Mouse Anti-BCMA Neutralizing Antibody, Mouse IgG1 (recommended for neutralizing assay)
BCA-M43-sds
MBS-K004 Human Human BCMA-coupled Magnetic Beads
BCA-HF2H1 Human FITC-Labeled Human BCMA / TNFRSF17 Protein, His Tag
BCA-HF2H1-structure
BCA-HF2H1-sds
BCA-H5253 Human Human BCMA / TNFRSF17 Protein, Mouse IgG2a Fc Tag, low endotoxin
BCA-H5253-structure
BCA-H5253-sds
BCA-M52H3 Mouse Mouse BCMA / TNFRSF17 Protein, His Tag
BCA-M52H3-structure
BCA-M52H3-sds
BCA-H82E4 Human Biotinylated Human BCMA / TNFRSF17 Protein, His,Avitag™, premium grade
BCA-H82E4-structure
BCA-H82E4-sds
BCA-H5259 Human Human BCMA / TNFRSF17 Protein, Llama IgG2b Fc Tag, low endotoxin
BCA-H5259-structure
BCA-H5259-sds
BCA-C52H7 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, His Tag
BCA-C52H7-structure
BCA-C52H7-sds
BCA-M82F0 Mouse Biotinylated Mouse BCMA / TNFRSF17 Protein, Fc,Avitag™
BCA-M82F0-structure
BCA-M82F0-sds
BCA-M5258 Mouse Mouse BCMA / TNFRSF17 Protein, Fc Tag
BCA-M5258-structure
BCA-M5258-sds
BCA-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Fc Tag
BCA-C5253-structure
BCA-C5253-sds
BCA-C82F4 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque BCMA / TNFRSF17 Protein, Fc,Avitag™
BCA-C82F4-structure
BCA-C82F4-sds
BC7-H82F0 Human Biotinylated Human BCMA / TNFRSF17 Protein, Fc,Avitag™, premium grade
BC7-H82F0-structure
BC7-H82F0-sds
BCA-H522y Human Human BCMA / TNFRSF17 Protein, His Tag, premium grade
BCA-H522y-structure
BCA-H522y-sds
BCA-H522y-hplc
BCA-HF254 Human FITC-Labeled Human BCMA / TNFRSF17 Protein, Fc Tag
BCA-HF254-structure
BCA-HF254-sds
BC7-H5254 Human Human BCMA / TNFRSF17 Protein, Fc Tag, premium grade
BC7-H5254-structure
BC7-H5254-sds
BC7-H5254-hplc
ACRO Quality

Part of Bioactivity data

BCA-HA2H8-Cell-based assay
 BCMA CAR_T

5e5 of anti-BCMA CAR-293 cells were stained with 100 μL of 1 μg/mL of AF488-Labeled Human BCMA, His Tag (Cat. No. BCA-HA2H8) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). AF488 signal was used to evaluate the binding activity (QC tested).

BCA-M43-SPR
 BCMA SPR

Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

BCA-H522y-SPR
 BCMA SPR

Anti-Human BCMA MAb (human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human BCMA, His Tag, premium grade (Cat. No. BCA-H522y) with an affinity constant of 13.0 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

TNFRSF17,CD269,BCM,BCMA

Background

Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Belantamab mafodotin GSK-2857916; GSK2857916 Approved Glaxosmithkline Plc BLENREP EU Multiple Myeloma Glaxosmithkline (Ireland) Ltd 2020-08-05 Bone Marrow Neoplasms; Lymphoma, B-Cell; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Plasmablastic Lymphoma; Amyloidosis Details
Elranatamab PF-06863135 Approved Pfizer Pharmaceuticals Ltd (China), Pfizer Inc Elrexfio, ELREXFIO United States Multiple Myeloma Pfizer Inc 2023-08-14 Bone Marrow Neoplasms; Multiple Myeloma Details
Teclistamab JNJ-64007959; JNJ-64007957; JNJ-7957 Approved Janssen Global Services Llc, Genmab A/S TECAYLI EU Multiple Myeloma Janssen-Cilag International Nv 2022-08-23 Hematologic Diseases; Hematologic Neoplasms; Smoldering Multiple Myeloma; Multiple Myeloma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Autologous anti-BCMA/GPRC5D CAR-T cell therapy (Xuzhou Medical University) Phase 2 Clinical Xuzhou Medical University (Xzmu) Multiple Myeloma Details
CAR-BCMA(Sheba Medical Center) Phase 2 Clinical Sheba Medical Center, Israel Multiple Myeloma Details
Anti-BCMA CAR T (Nanjing Kati Medical Technology) Phase 1 Clinical Nanjing Kati Medical Technology Co Ltd Multiple Myeloma Details
ISB-2001 ISB-2001 Phase 1 Clinical Ichnos Sciences Sa Multiple Myeloma Details
AMG-224 AMG-224 Phase 1 Clinical Amgen Inc Multiple Myeloma Details
ACLX-001 ACLX-001 Phase 1 Clinical Arcellx Inc Multiple Myeloma Details
Anti-BCMA/CD19 CAR-T Therapy(University College London) Phase 1 Clinical University College London Multiple Myeloma Details
C-4-29 Phase 1 Clinical Chongqing Precision Biotechnology Co Ltd Carcinoma, Renal Cell; Multiple Myeloma Details
IBI-346 IBI-346 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Multiple Myeloma Details
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Multiple Myeloma; Lupus Erythematosus, Systemic; Waldenstrom Macroglobulinemia Details
WVT-078(Novartis Pharma) WVT-078 Phase 1 Clinical Novartis Pharma Ag Multiple Myeloma Details
ABBV-383 ABBV-383; TNB-383B Phase 3 Clinical Teneobio Inc, Abbvie Inc Multiple Myeloma Details
spCART-269 spCART-269 Phase 1 Clinical Shanghai Tongji Hospital, Tongji University School Of Medicine Multiple Myeloma Details
CART-BCMA MTV-273; CART-BCMA Phase 1 Clinical University Of Pennsylvania Rejection of renal transplantation; Renal Insufficiency; Multiple Myeloma; Kidney Failure, Chronic Details
EMB-06 EMB-06; EMB06 Phase 2 Clinical Shanghai Epimab Biotherapeutics, Inc Multiple Myeloma Details
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) Phase 2 Clinical Chongqing Precision Biotechnology Co Ltd Lymphoma, B-Cell; Multiple Myeloma; Lymphoma, Non-Hodgkin Details
ALLO-715 ALLO-715 Phase 1 Clinical Allogene Therapeutics Inc, Cellectis Sa Multiple Myeloma Details
Pavurutamab AMG-701 Phase 1 Clinical Amgen Inc Multiple Myeloma Details
MCM-998 MCM-998; LXG-250 Phase 1 Clinical Novartis Pharma Ag Multiple Myeloma Details
BCMA CAR-T Cells (Pregene) PRG-1801 Phase 2 Clinical Shenzhen Prekin Biopharmaceutical Co Ltd Multiple Myeloma Details
BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech) LCAR-BCX Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Multiple Myeloma Details
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) Phase 1 Clinical Eugia Pharma Specialities Ltd, Actavis Inc Multiple Myeloma Details
Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian) Descartes-08 Phase 2 Clinical Cartesian Therapeutics Inc Myasthenia Gravis; Multiple Myeloma; Lupus Erythematosus, Systemic Details
bb-21217 bb-21217 Phase 1 Clinical Bluebird Bio Inc, Bristol-Myers Squibb Company Multiple Myeloma Details
Pacanalotamab AMG-420; BI-836909 Phase 1 Clinical Micromet Inc Multiple Myeloma Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) Phase 2 Clinical People'S Liberation Army General Hospital Military Service Multiple Myeloma Details
Humanized CART Directed Against BCMA ARI-0002h Phase 2 Clinical Instituto De Salud Carlos Iii Multiple Myeloma Details
Descartes-11 Descartes-11; Descartes-011 Phase 2 Clinical Cartesian Therapeutics Inc Multiple Myeloma Details
HDP-101 HDP-101; HDP101-ATAC Phase 2 Clinical Heidelberg Paraproteinemias; Multiple Myeloma Details
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) BCMA-CART Phase 2 Clinical Hrain Biotechnology Co Ltd Multiple Myeloma Details
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) Phase 3 Clinical The First Affiliated Hospital Of Soochow University Leukemia; Multiple Myeloma Details
Orvacabtagene autoleucel ET-140; FCARH-143; ET140-CAR; MCARH-171; JCARH-125 Phase 2 Clinical Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Eureka Therapeutics Inc Multiple Myeloma Details
BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) Phase 2 Clinical Shanghai YaKe Biotechnology Co Ltd Neoplasms; Multiple Myeloma Details
CART-BCMA(Simnova) SNC-102(Simnova); SNC102(Simnova) Phase 2 Clinical Shanghai Simnova Biotechnology Co Ltd Multiple Myeloma Details
AUTO-2 AUTO-2; SUB-96123 Phase 1 Clinical Autolus Multiple Myeloma Details
Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) Phase 1 Clinical Chongqing Xinqiao Hospital Multiple Myeloma Details
Motacabtagene lurevgedleucel CTX-120 Phase 1 Clinical Crispr Therapeutics Ag Multiple Myeloma Details
GR-1803 GR-1803 Phase 1 Clinical Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd Multiple Myeloma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken